Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease (COPD)
Intervention:   Drug: Albuterol Spiromax®
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries
Not yet recruiting – verified May 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.